Once again Goldman Small Cap Research has showed up with a report on Pharmacyte Biotech Inc (OTCMKTS:PMCB), however, investors should pause to learn that the report is ‘sponsored’. The new research report throws light on how the company is all set to launch a Human Clinical trial.
What is there in the report?
Report written by analyst Rob Goldman stressed on the strong story building around Pharmacyte Biotech Inc (OTCMKTS:PMCB) following the formation of the company’s International Diabetes Consortium. The report indicated that the Consortium through its unique and collaborated expertise will help lead the company in diabetes market. Analyst elucidated that the 16-member Consortium has already started working on the company’s technology driven diabetes research projects across Europe and Asia.
The research report noted that unlike the typical preclinical research and animal studies, the Consortium led multiple studies are modeled differently. It said that these studies are designed with the intention of speeding up the R&D process. Thus, such form of streamlining should pave the way for Pharmacyte Biotech Inc (OTCMKTS:PMCB) to jump into human clinical trials at the earliest, the report highlighted. Also, Goldman stressed on Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s proprietary technology that allows its to use Melligen cells in treating diabetes. The company’s technology has already been proved effective in reversing diabetes in a recent study.
Sponsored report
The emergence of successful story around Pharmacyte Biotech Inc (OTCMKTS:PMCB) live-cell encapsulation technology has given wings to the members of the Consortium, who are committed to find a solid evidence to put the company’s technology in track of human trials. But, still the word, ‘sponsored article’, attached with the report should drive investors with caution. The report must be perceived merely as a forward-looking statement, which may or may not convert into reality.
During the last session, the stock of Pharmacyte Biotech Inc (OTCMKTS:PMCB) shed 1.68% to close at $0.153. The average volume of shares on the day stood at 5.19 million.
